INmune Bio

Historical price data

INmune Bio is a clinical-stage biotech focused on precisely modulating the innate immune system to treat Alzheimer's disease and cancer. Its strategy centers on two distinct platforms: XPro1595, a dominant-negative TNF inhibitor that neutralizes only the soluble form driving pathology, and INKmune, an in vivo NK cell primer. The company is advancing multiple Phase 2 trials, with a development philosophy anchored in patient biology and clinically relevant metrics.

Two platforms: 1) XPro1595, a dominant-negative protein that selectively neutralizes soluble TNF to quell pathological inflammation; 2) INKmune, an off-the-shelf cellular therapy that primes a patient's own NK cells in vivo to attack cancer.

In Alzheimer's, competes by offering a selective anti-inflammatory approach distinct from broad anti-TNF failures and the dominant amyloid paradigm. In NK cell therapy, competes with complex ex vivo/CAR-NK platforms by offering a simpler, in vivo priming strategy aimed at better safety and scalability.